Novo’s Rybelsus Pill Set To Disrupt Europe’s Diabetes Market
Rybelsus, the first oral GLP-1 treatment for type 2 diabetes, will likely secure EU approval in a couple of months.
Rybelsus, the first oral GLP-1 treatment for type 2 diabetes, will likely secure EU approval in a couple of months.